Lifevantage Corp (LFVN) stock
LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 16/3023% below fair value
$4.97−0.07 (-1.39%)
Close on Nov 13, 2026Market cap $62.26MP/E 23.7Yield 3.72%
Lifevantage r&d expenses
Research and development expenses are spending on new products and technology.
Lifevantage's R&D Expenses for the twelve months ending Sep 30, 2026 was $800.00K, down 38.5% year over year. For fiscal 2026 it was $1.00M, down 28.6% from the year before. Over ten years it grew 0.0% a year on average. The highest annual figure on record is $2.90M in fiscal 2013.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $1.00M | -28.6% |
| FY2025 | Jun 30, 2025 | $1.40M | +100.0% |
| FY2024 | Jun 30, 2024 | $700.00K | +16.7% |
| FY2023 | Jun 30, 2023 | $600.00K | -14.3% |
| FY2022 | Jun 30, 2022 | $700.00K | 0.0% |
| FY2021 | Jun 30, 2021 | $700.00K | -22.2% |
| FY2020 | Jun 30, 2020 | $900.00K | -18.2% |
| FY2019 | Jun 30, 2019 | $1.10M | -8.3% |
| FY2018 | Jun 30, 2018 | $1.20M | +9.1% |
| FY2017 | Jun 30, 2017 | $1.10M | +10.0% |
| FY2016 | Jun 30, 2016 | $1.00M | -58.3% |
| FY2015 | Jun 30, 2015 | $2.40M | +20.0% |
| FY2014 | Jun 30, 2014 | $2.00M | -31.0% |
| FY2013 | Jun 30, 2013 | $2.90M | +107.1% |
| FY2012 | Jun 30, 2012 | $1.40M | +175.0% |
| FY2011 | Jun 30, 2011 | $509.00K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Sep 30, 2026 | $200.00K | -33.3% |
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $200.00K | -50.0% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $200.00K | -50.0% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $200.00K | 0.0% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $300.00K | 0.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $400.00K | +100.0% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $400.00K | +100.0% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $200.00K | +100.0% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $300.00K | +50.0% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $200.00K | 0.0% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $200.00K | 0.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $100.00K | -50.0% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $200.00K | +100.0% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $200.00K | +100.0% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $200.00K | +100.0% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $200.00K | 0.0% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $100.00K | -50.0% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $100.00K | 0.0% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $100.00K | -50.0% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $200.00K | 0.0% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $200.00K | 0.0% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $100.00K | 0.0% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $200.00K | 0.0% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $200.00K | -33.3% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $200.00K | 0.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $100.00K | 0.0% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $200.00K | +100.0% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $300.00K | -40.0% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $200.00K | -50.0% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $100.00K | -75.0% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $100.00K | -66.7% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $500.00K | +66.7% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $400.00K | +33.3% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $400.00K | +33.3% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $300.00K | +50.0% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $300.00K | 0.0% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $300.00K | – |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $300.00K | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $200.00K | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $300.00K | – |
See a number that looks wrong?